Literature DB >> 7966589

Effect of core protein phosphorylation by protein kinase C on encapsidation of RNA within core particles of hepatitis B virus.

M Kann1, W H Gerlich.   

Abstract

Phosphorylation of core particles derived either from hepatitis B viruses or from livers of hepatitis B-infected individuals has been long recognized, but the nature and function of the phosphorylating enzyme remained unknown. By immunoblotting with a monoclonal antibody, we have now detected protein kinase C within the liver-derived core particles. To study the significance of the encapsidated protein kinase C for the viral life cycle, we established an in vitro assembly system consisting of Escherichia coli-expressed core protein, protein kinase C, and in vitro-synthesized hepatitis B virus RNA. Phosphorylation of the core protein led to a reduced RNA encapsidation capacity of the core particles. Furthermore, RNA and protein kinase C competed for their target sequence, which is the carboxy-terminal arginine-rich domain of the core protein. This finding implies that phosphorylation of the nucleic acid binding site in the core protein occurs within the particles after encapsidation of protein kinase C, pregenomic RNA, and viral polymerase at a later step during viral genome maturation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966589      PMCID: PMC237262          DOI: 10.1128/JVI.68.12.7993-8000.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  31 in total

1.  The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis.

Authors:  G H Wang; C Seeger
Journal:  Cell       Date:  1992-11-13       Impact factor: 41.582

2.  Phosphorylation in the carboxyl-terminal domain of the capsid protein of hepatitis B virus: evaluation with a monoclonal antibody.

Authors:  A Machida; H Ohnuma; F Tsuda; A Yoshikawa; Y Hoshi; T Tanaka; S Kishimoto; Y Akahane; Y Miyakawa; M Mayumi
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

3.  Expression of functional hepatitis B virus polymerase in yeast reveals it to be the sole viral protein required for correct initiation of reverse transcription.

Authors:  J E Tavis; D Ganem
Journal:  Proc Natl Acad Sci U S A       Date:  1993-05-01       Impact factor: 11.205

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  A micromolar pool of antigenically distinct precursors is required to initiate cooperative assembly of hepatitis B virus capsids in Xenopus oocytes.

Authors:  M Seifer; S Zhou; D N Standring
Journal:  J Virol       Date:  1993-01       Impact factor: 5.103

6.  Topological analysis of the hepatitis B virus core particle by cysteine-cysteine cross-linking.

Authors:  M Nassal; A Rieger; O Steinau
Journal:  J Mol Biol       Date:  1992-06-20       Impact factor: 5.469

7.  Carboxy-terminal truncations of the HBV core protein affect capsid formation and the apparent size of encapsidated HBV RNA.

Authors:  B Beames; R E Lanford
Journal:  Virology       Date:  1993-06       Impact factor: 3.616

8.  Production of hepatitis B virus nucleocapsidlike core particles in Xenopus oocytes: assembly occurs mainly in the cytoplasm and does not require the nucleus.

Authors:  S L Zhou; D N Standring
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

9.  Hepatitis B virus capsid particles are assembled from core-protein dimer precursors.

Authors:  S Zhou; D N Standring
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

10.  RNA- and DNA-binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication.

Authors:  T Hatton; S Zhou; D N Standring
Journal:  J Virol       Date:  1992-09       Impact factor: 5.103

View more
  69 in total

1.  Core protein phosphorylation modulates pregenomic RNA encapsidation to different extents in human and duck hepatitis B viruses.

Authors:  E V Gazina; J E Fielding; B Lin; D A Anderson
Journal:  J Virol       Date:  2000-05       Impact factor: 5.103

2.  Nuclear pore complex is able to transport macromolecules with diameters of about 39 nm.

Authors:  Nelly Panté; Michael Kann
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

3.  Interaction between hepatitis B virus core protein and reverse transcriptase.

Authors:  L Lott; B Beames; L Notvall; R E Lanford
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

4.  Nuclear import of hepatitis B virus capsids and release of the viral genome.

Authors:  Birgit Rabe; Angelika Vlachou; Nelly Panté; Ari Helenius; Michael Kann
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-08       Impact factor: 11.205

5.  Analyses of phosphorylation events in the rubella virus capsid protein: role in early replication events.

Authors:  LokMan J Law; Carolina S Ilkow; Wen-Pin Tzeng; Matthew Rawluk; David T Stuart; Teryl K Frey; Tom C Hobman
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

6.  Modeling Viral Capsid Assembly.

Authors:  Michael F Hagan
Journal:  Adv Chem Phys       Date:  2014       Impact factor: 1.000

Review 7.  Hepatitis B virus morphogenesis.

Authors:  Volker Bruss
Journal:  World J Gastroenterol       Date:  2007-01-07       Impact factor: 5.742

8.  Maturation-associated destabilization of hepatitis B virus nucleocapsid.

Authors:  Xiuji Cui; Laurie Ludgate; Xiaojun Ning; Jianming Hu
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

9.  Phosphorylation of the porcine reproductive and respiratory syndrome virus nucleocapsid protein.

Authors:  Sarah K Wootton; Raymond R R Rowland; Dongwan Yoo
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Tumor necrosis factor activates a conserved innate antiviral response to hepatitis B virus that destabilizes nucleocapsids and reduces nuclear viral DNA.

Authors:  Robyn Puro; Robert J Schneider
Journal:  J Virol       Date:  2007-05-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.